| 1 |
NCT01412021 |
Active, not recruiting |
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis |
- Arthritis, Juvenile Rheumatoid
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Serum Matrix metalloprotease-3 level
- Weight
- Anti-cyclic citrullinated peptides antibodies
- (and 4 more...)
|
375 |
All |
up to 99 Years (Child, Adult, Senior) |
NCT01412021 |
P12-769 |
|
August 1, 2011 |
June 30, 2018 |
June 30, 2018 |
August 8, 2011 |
February 16, 2018 |
|
- Kurume University Hospital
久留米市, Fukuoka, Japan - Gunma University Hospital
Maebashi-shi, Gunma, Japan - Kitasato University Hospital
Sagamihara-shi, Kanagawa, Japan - (and 141 more...)
|
| 2 |
NCT00731965 |
Completed |
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis |
- Arthritis, Juvenile Rheumatoid
|
- Biological: Measles, Mumps, Rubella vaccination
|
Interventional |
Phase 4 |
- N.M. Wulffraat
- University Medical Center Groningen
- VU University Medical Center
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- JIA disease activity, defined by the core set criteria for JIA and number of flares
- Immunological reaction to MMR vaccination and regulatory mechanisms induced by MMR, measured by number and function of MMR-specific T cells and cytokine profiles
|
140 |
All |
4 Years to 9 Years (Child) |
NCT00731965 |
VAART
ISRCTN12271664 |
VAART |
May 2008 |
May 2012 |
May 2012 |
August 11, 2008 |
July 30, 2014 |
|
- Academic hospital Maastricht
Maastricht, Limburg, Netherlands - VU University Medical Center Amsterdam
Amsterdam, Netherlands - University Medical Center Groningen, Beatrix Children's Hospital
Groningen, Netherlands - (and 2 more...)
|
| 3 |
NCT02067962 |
Unknown † |
Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing |
- Arthritis, Juvenile Rheumatoid
|
|
Interventional |
Not Applicable |
- University Hospital, Montpellier
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Identification of new genes by Next Generation Squencing (NGS)
|
30 |
All |
1 Month to 40 Years (Child, Adult) |
NCT02067962 |
UF9258 |
GenesinJIA |
March 2014 |
December 2017 |
|
February 20, 2014 |
February 20, 2014 |
|
|
| 4 |
NCT00637780 |
Terminated
Has Results |
Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis |
- Arthritis, Juvenile Rheumatoid
|
|
Interventional |
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Sulfasalazine Steady State Maximum Plasma Concentration (Cmax) and Predose Concentration (Cmin)
- Sulfasalazine Time for Cmax (Tmax) at Steady State
- Sulfasalazine Area Under the Concentration-time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) at Steady State
- (and 9 more...)
|
2 |
All |
6 Years to 17 Years (Child) |
NCT00637780 |
A0031005 |
|
June 2010 |
January 2014 |
January 2014 |
March 18, 2008 |
February 23, 2017 |
February 23, 2017 |
- University Hospitals Case Medical Center
Cleveland, Ohio, United States - Private Office
Guadalajara, Jalisco, Mexico
|
| 5 |
NCT00426218 |
Completed |
Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) |
- Arthritis, Juvenile Rheumatoid
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety, tolerability and immunogenicity of subcutaneous (s.c.) ACZ885
- To assess the initial efficacy profile of s.c. ACZ885: % responder to treatment and time to relapse and control the systemic manifestations of SJIA such as fever.
- pharmacokinetics of ACZ885
- (and 4 more...)
|
26 |
All |
4 Years to 20 Years (Child, Adult) |
NCT00426218 |
CACZ885A2203 |
|
December 2006 |
March 2010 |
|
January 24, 2007 |
August 9, 2011 |
|
- Novartis Investigative site
Origgio, Italy
|
| 6 |
NCT00688545 |
Terminated
Has Results |
Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis |
- Arthritis, Juvenile Rheumatoid
|
- Drug: Celecoxib
- Drug: nsNSAIDs
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- JIA Concomitant Medications
|
275 |
All |
2 Years to 17 Years (Child) |
NCT00688545 |
A3191344 |
SINCERE |
April 2009 |
January 2012 |
January 2012 |
June 3, 2008 |
August 15, 2013 |
July 19, 2013 |
- Pfizer Investigational Site
Phoenix, Arizona, United States - Pfizer Investigational Site
Little Rock, Arkansas, United States - Pfizer Investigational Site
Washington, District of Columbia, United States - (and 24 more...)
|
| 7 |
NCT00279747 |
Completed |
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) |
- Arthritis, Juvenile Rheumatoid
|
- Drug: meloxicam 0.25 mg/kg
- Drug: meloxicam 0.125 mg/kg
- Drug: naproxen 10 mg/kg
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Response rates according to ACR Ped 30
- Global assessment of overall disease activity by investigator
- Parent global assessment of overall well-being
- (and 20 more...)
|
226 |
All |
2 Years to 16 Years (Child) |
NCT00279747 |
107.208 |
|
September 2000 |
January 2003 |
January 2003 |
January 20, 2006 |
November 1, 2013 |
|
- Landes-Kinderklinik Linz
Linz, Austria - Univ.-Klinik für Kinder- und Jugendheilkunde Wien
Wien, Austria - Gottfried Preyersches Kinderspital d. Stadt Wien
Wien, Austria - (and 31 more...)
|
| 8 |
NCT00034853 |
Completed |
Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) |
- Arthritis, Juvenile Rheumatoid
|
- Drug: meloxicam oral suspension
- Drug: naproxen oral suspension
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
|
- Responder rate by core set of outcome criteria (Juvenile Rheumatoid Arthritis Pediatric 30): global assessment disease activity; functional disability, number joints arthritis, limited motion; erythrocyte sedimentation rate;
- Individual core set outcome criteria; final global assessment of efficacy; tolerability; AE incidence and intensity; withdrawals; acetaminophen consumption; safety labs: physical examination; hospitalization for gastrointestinal (GI) SAE, GI AE
|
180 |
All |
2 Years to 17 Years (Child) |
NCT00034853 |
107.235 |
|
December 2000 |
June 2003 |
|
May 3, 2002 |
November 1, 2013 |
|
- 107.235.23 Arkansas Children's Hospital
Little Rock, Arkansas, United States - 107.235.17 Valley Children's Hospital
Madera, California, United States - 107.235.37
San Diego, California, United States - (and 34 more...)
|
| 9 |
NCT00807846 |
Completed
Has Results |
A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects |
- Arthritis, Juvenile Rheumatoid
|
- Drug: Celecoxib
- Drug: Naproxen
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Systolic Blood Pressure (SBP) at Week 6/Final Visit
- Change From Baseline to Week 2 in SBP.
- Change From Baseline in SBP at Week 4.
- (and 7 more...)
|
201 |
All |
2 Years to 17 Years (Child) |
NCT00807846 |
A3191342 |
|
September 2009 |
December 2012 |
December 2012 |
December 12, 2008 |
November 11, 2015 |
November 11, 2015 |
- Catalina Pointe Clinical Research, Inc.
Tucson, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - Children's Hospital-San Diego
San Diego, California, United States - (and 36 more...)
|
| 10 |
NCT02030613 |
Completed |
Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Etanercept concentration-time courses
- Wallace criteria
- anti-etanercept antibodies levels
- (and 3 more...)
|
126 |
All |
4 Years to 17 Years (Child) |
NCT02030613 |
P111102 |
Etaplus |
October 1, 2013 |
February 28, 2017 |
March 30, 2017 |
January 8, 2014 |
July 5, 2017 |
|
- Hospital Necker
Paris, France
|
| 11 |
NCT01399281 |
Recruiting |
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents and/or Methotrexate |
- Juvenile Idiopathic Arthritis
|
|
Observational |
|
- Istituto Giannina Gaslini
- Members of the PRINTO network (PRINTO at www.printo.it)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety in patients with JIA on biologics/MTX from 3 to 10 years from drug initiation
- Long-term efficacy in patients with JIA on biologics/MTX from 3 to 10 years from drug initiation
- Predictors of safety from 3 to 10 years from drug initiation
- (and 5 more...)
|
9000 |
All |
6 Months to 30 Years (Child, Adult) |
NCT01399281 |
EU 260353 |
PharmaChild |
December 2011 |
December 2021 |
December 2021 |
July 21, 2011 |
March 5, 2018 |
|
- IRCCS G. Gaslini
Genoa, Italy
|
| 12 |
NCT02218580 |
Recruiting |
Massage Therapy in Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Other: Massage therapy
- Other: Standard care
|
Interventional |
Not Applicable |
- McGill University Health Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recruitment rate
- Retention rate
- Program adherence
- (and 11 more...)
|
30 |
All |
5 Years to 17 Years (Child) |
NCT02218580 |
CRA (CIORA grant #4) |
|
May 2015 |
January 2019 |
January 2019 |
August 18, 2014 |
March 30, 2018 |
|
- Montreal Children's Hospital - Glen site
Montreal, Quebec, Canada
|
| 13 |
NCT00690573 |
Completed
Has Results |
Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis |
- Juvenile Rheumatoid Arthritis
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16
- Number of Subjects Achieving PedACR50 and PedACR70 Responses at Week 16
- Number of Subjects Achieving PedACR 30/50/70 Responses
- (and 2 more...)
|
25 |
All |
4 Years to 17 Years (Child) |
NCT00690573 |
M10-240 |
|
May 2008 |
March 2010 |
September 2011 |
June 4, 2008 |
September 10, 2012 |
April 1, 2011 |
- Site Reference ID/Investigator# 47248
Aichi, Japan - Site Reference ID/Investigator# 47253
Fukuoka, Japan - Site Reference ID/Investigator# 47251
Hyogo, Japan - (and 9 more...)
|
| 14 |
NCT00095173 |
Completed
Has Results |
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis |
- Juvenile Rheumatoid Arthritis
|
- Drug: Abatacept
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B)
- Number of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B)
- Number of Participants With Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs During Open-Label Lead-In Phase (Period A)
- (and 12 more...)
|
214 |
All |
6 Years to 17 Years (Child) |
NCT00095173 |
IM101-033 |
|
December 2003 |
June 2006 |
November 2011 |
November 2, 2004 |
January 18, 2017 |
January 18, 2017 |
- Omaha, Nebraska, United States
- Livingston, New Jersey, United States
- New Hyde Park, New York, United States
- (and 33 more...)
|
| 15 |
NCT00534495 |
Completed
Has Results |
Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 2 |
- Montefiore Medical Center
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are Taking Corticosteroids
- Number of Serious Adverse Events,Adverse Events, Infections, Development of MAS
- Number of Participants With Response as Determined by JIA ACR50 and JIA ACR70
- (and 3 more...)
|
71 |
All |
18 Months to 19 Years (Child, Adult) |
NCT00534495 |
N01 AR070015
268200700015C-2-0-0
HHSN2682007000015C |
|
November 2008 |
June 2013 |
June 2013 |
September 26, 2007 |
December 11, 2015 |
December 11, 2015 |
- Montefiore Medical Center
Bronx, New York, United States
|
| 16 |
NCT02977416 |
Recruiting |
Oxidation Rates of the Different Substrates During Exercise in Children and Adolescents With Juvenile Idiopathic Arthritis. Case-control Study and Cases Treated / Cases Not Treated With Anti-TNFα |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Not Applicable |
- University Hospital, Clermont-Ferrand
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
- Percentage variation of the maximal fat oxidative rate during an exercise between JIA and healthy children. Timing:
- Percentage variation of substrates oxidative crossing point during an exercise.
- Description of the contribution of energy systems during supra-maximal physical exercise
|
66 |
All |
8 Years to 18 Years (Child, Adult) |
NCT02977416 |
CHU-0295
2016-A01262-49 |
OSE-JIA |
November 2016 |
May 2020 |
September 2020 |
November 30, 2016 |
December 5, 2016 |
|
- CHU Clermon-Ferrand
Clermont-Ferrand, France
|
| 17 |
NCT03383263 |
Not yet recruiting |
A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®) |
- Polyarticular Juvenile Arthritis
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Assessing Humira persistence
- Proportion of patients with Humira adherence
- Proportion of patients with 30% American College of Rheumatology (ACR) pediatric responses
- (and 14 more...)
|
70 |
All |
2 Years to 18 Years (Child, Adult) |
NCT03383263 |
P17-164 |
|
March 31, 2018 |
March 31, 2020 |
March 31, 2020 |
December 26, 2017 |
March 19, 2018 |
|
|
| 18 |
NCT00775437 |
Completed
Has Results |
Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 3 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
- Mean Serum Adalimumab Trough Concentrations at Week 0, Week 12, and Week 24
- Hemoglobin: Mean Change From Baseline to Each Visit
- (and 44 more...)
|
32 |
All |
2 Years to 4 Years (Child) |
NCT00775437 |
M10-444
2009-013091-40 |
|
March 2009 |
March 2013 |
March 2013 |
October 20, 2008 |
January 26, 2016 |
January 26, 2016 |
|
| 19 |
NCT01469897 |
Completed |
Cost of Care for Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Direct and indirect costs
- Health related quality of life questionnaires
|
165 |
All |
Child, Adult, Senior |
NCT01469897 |
CCF 11-291 |
|
January 2012 |
December 2014 |
March 2017 |
November 10, 2011 |
January 17, 2018 |
|
- Children's Hospital & Medical Center
Omaha, Nebraska, United States - The Cleveland Clinic
Cleveland, Ohio, United States - Dell Childrens Medical Center of Central Texas
Austin, Texas, United States
|
| 20 |
NCT01436019 |
Unknown † |
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Observational |
|
- Blood Transfusion Centre of Slovenia
- University Medical Centre Ljubljana
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Determination of the presence and quantification of anti-drug antibodies by ELISA or other immunoassay.
- Determination of the presence and quantification of the serum level of the anti-TNF agent used for JIA therapy by ELISA or other immunoassay.
- Determination of the presence and quantification of the isotypes and subtypes of the anti-drug antibodies by ELISA or other immunoassay.
- Time to first detection of anti-drug antibodies.
|
100 |
All |
1 Year to 16 Years (Child) |
NCT01436019 |
BTC-PK-1 |
|
October 2011 |
October 2012 |
December 2012 |
September 19, 2011 |
September 19, 2011 |
|
- University Medical Centre
Ljubljana, Slovenia
|
| 21 |
NCT01166750 |
Completed
Has Results |
Jointstrong Intervention for Juvenile Arthritis |
|
- Behavioral: CD-ROM
- Behavioral: Wait-list Control Group
|
Interventional |
Not Applicable |
- Michael Rapoff, Ph.D.
- University of Kansas Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain
- Mood and Stress
- Quality of Life
|
35 |
All |
8 Years to 12 Years (Child) |
NCT01166750 |
11154 |
|
April 2009 |
March 2011 |
May 2011 |
July 21, 2010 |
May 31, 2013 |
May 31, 2013 |
- University Of Kansas Medical Center
Kansas City, Kansas, United States
|
| 22 |
NCT03245801 |
Recruiting |
CAPRI National Juvenile Idiopathic Arthritis Registry |
- Juvenile Idiopathic Arthritis (JIA)
|
|
Observational |
|
- University of British Columbia
- Children's Hospital of Eastern Ontario
- The Hospital for Sick Children
- (and 11 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Proportion of Children with Clinical inactive disease
- Juvenile Arthritis Disease Activity Score
- Pain intensity
- (and 2 more...)
|
300 |
All |
up to 18 Years (Child, Adult) |
NCT03245801 |
H16-00309
UBC Number: F15-01938 |
|
February 1, 2017 |
February 1, 2026 |
February 1, 2026 |
August 10, 2017 |
August 10, 2017 |
|
- University of Calgary / Alberta Children's Hospital
Calgary, Alberta, Canada - University of Alberta
Edmonton, Alberta, Canada - BC Children's Hospital
Vancouver, British Columbia, Canada - (and 11 more...)
|
| 23 |
NCT02001844 |
Completed |
Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA |
- Arthritis, Juvenile Rheumatoid
|
- Device: Trial Foot Orthoses (FOs)
- Device: placebo foot orthoses (FOs)
|
Interventional |
Not Applicable |
- University of Newcastle, Australia
- Queen Margaret University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- effects of pre-formed semi-rigid FOs on Pain in Paediatric Rheumatology.
- effects of pre-formed semi-rigid FOs on Quality of Life in Paediatric Rheumatology.
- gait parameters when barefoot
- (and 2 more...)
|
60 |
All |
5 Years to 18 Years (Child, Adult) |
NCT02001844 |
JIA - FOs intervention |
|
May 2009 |
November 2012 |
May 2013 |
December 5, 2013 |
December 5, 2013 |
|
- Dr Andrea Coda - Lecturer Podiatry , School of Health & Science
Ourimbah, New South Wales, Australia - University of Newcastle, Podiatry, School of Health & Science
Ourimbah, New South Wales, Australia
|
| 24 |
NCT00868751 |
Terminated
Has Results |
Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis |
- Arthritis, Juvenile Rheumatoid
- Still's Disease, Juvenile Onset
|
|
Interventional |
Not Applicable |
- Tufts Medical Center
- Hoffmann-La Roche
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of Tocilizumab as Defined by Presence of an Equal to or Greater Than 30% Improvement in JIA Core Set (i.e. ACR JIA30 Response)
- Efficacy of Tocilizumab as Defined by Reduction of Oral Prednisone Dose by at Least 20%, or to Less Than 0.5mg/kg/Day, Whichever is of Lesser Daily Dose, While Maintaining an ACR JIA30 Response
- Number of Participants With at Least One Adverse Event
- (and 2 more...)
|
1 |
All |
2 Years to 16 Years (Child) |
NCT00868751 |
TMC-PRHEU-TCZ-01 |
|
March 2009 |
November 2009 |
June 2010 |
March 25, 2009 |
May 15, 2017 |
May 15, 2017 |
- Tufts Medical Center/Floating Hospital for Children
Boston, Massachusetts, United States
|
| 25 |
NCT03116763 |
Recruiting |
The iPeer2Peer Program for Adolescents With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Behavioral: iPeer2Peer Mentorship
- Other: Active Comparator: Control Group
|
Interventional |
Not Applicable |
- The Hospital for Sick Children
- Provincial Health Services Authority
- IWK Health Centre
- Children's Hospital of Eastern Ontario
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- TRANSITION-Q (measuring change)
- PedsQL Arthritis Module (measuring change)
- PROMIS Pain Interference (measuring change)
- (and 12 more...)
|
262 |
All |
12 Years to 18 Years (Child, Adult) |
NCT03116763 |
1000054878 |
iPeer2Peer |
March 28, 2017 |
May 31, 2019 |
September 30, 2019 |
April 17, 2017 |
April 17, 2017 |
|
- BC Children's Hospital
Vancouver, British Columbia, Canada - The IWK Health Centre
Halifax, Nova Scotia, Canada - Children's Hospital of Eastern Ontario (CHEO)
Ottawa, Ontario, Canada - The Hospital for Sick Children
Toronto, Ontario, Canada
|
| 26 |
NCT03092427 |
Recruiting |
Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA) |
- Juvenile Idiopathic Arthritis
|
- Dietary Supplement: VSL#3
- Other: Placebo
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- To evaluate the impact of a regular intake of probiotic VSL#3 in addition to standard treatment in patients with JIA on the clinical activity
- To evaluate the impact of a regular intake of probiotic VSL#3 in addition to standard treatment in patients with JIA on the intestinal microbiota.
|
120 |
All |
1 Year to 7 Years (Child) |
NCT03092427 |
P150934 |
PERMAJI |
September 4, 2017 |
May 2019 |
May 2020 |
March 27, 2017 |
November 7, 2017 |
|
- Robert Debre Hospital
Paris, France
|
| 27 |
NCT03301883 |
Recruiting |
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA) |
- Juvenile Idiopathic Arthritis
|
- Drug: Tocilizumab
- Drug: NSAIDs
- Drug: CSs
- Drug: MTX
|
Interventional |
Phase 4 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (JIA ACR30) Response With Absence of Fever, at Week 12
- Percentage of Participants Achieving JIA ACR30 Response With Absence of Fever, at Week 52
- Percentage of Participants With 30 Percent (%), 50%, 70%, and 90% Improvement From Baseline in JIA Core Set Parameters
- (and 11 more...)
|
65 |
All |
2 Years to 17 Years (Child) |
NCT03301883 |
YA39368 |
|
March 30, 2018 |
November 27, 2019 |
December 2, 2020 |
October 4, 2017 |
February 21, 2018 |
|
- Capital Institute of Pediatrics
Beijing City, China - Beijing Children's Hospital, Capital Medical University; rheumatism
Beijing City, China - Children's Hospital Chongqing Medical university
Chongqing, China
|
| 28 |
NCT00511329 |
Terminated
Has Results |
Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease |
- Arthritis, Juvenile Rheumatoid
- Crohn Disease
|
- Drug: somatropin [rDNA origin] for injection
|
Interventional |
Phase 2
Phase 3 |
- Nationwide Children's Hospital
- Pfizer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Primary Outcome Variables Will be Height and Weight Z Score.
- Secondary Outcome Variables Will Include Change in Lean Body Mass, Change in Bone Mineral Content, Change in Inflammatory Mediated Cytokine Levels and Change in Bone Turnover.
|
10 |
All |
5 Years to 17 Years (Child) |
NCT00511329 |
GA628132 |
|
August 2007 |
May 2010 |
May 2010 |
August 3, 2007 |
April 12, 2018 |
April 12, 2018 |
- Columbus Children's Hospital
Columbus, Ohio, United States
|
| 29 |
NCT01230827 |
Terminated
Has Results |
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) |
- Juvenile Idiopathic Arthritis
|
- Drug: CNTO 148 (Golimumab)
- Drug: Placebo
- Drug: Methotrexate
|
Interventional |
Phase 3 |
- Janssen Research & Development, LLC
- Schering-Plough
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants With American College of Rheumatology (ACR) 30 Response at Week 16 Who Did Not Experienced a Flare of Disease Through Week 48
- Percentage of Participants With American College of Rheumatology (ACR) 30 Response at Week 48
- Percentage of Participants With American College of Rheumatology (ACR) 30 Response Who Had Inactive Disease at Week 48
- Percentage of Participants Who Achieved Clinical Remission While on Medication for Juvenile Idiopathic Arthritis (JIA) at Week 48
|
173 |
All |
2 Years to 18 Years (Child, Adult) |
NCT01230827 |
CR017089
CNTO148JIA3001
2009-015019-42 |
|
December 2010 |
September 2013 |
May 2014 |
October 29, 2010 |
April 4, 2016 |
September 29, 2014 |
- Los Angeles, California, United States
- San Francisco, California, United States
- Augusta, Georgia, United States
- (and 32 more...)
|
| 30 |
NCT00001614 |
Completed |
The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis |
- Arthritis, Juvenile Rheumatoid
- Uveitis
|
- Drug: Chicken type II collagen
|
Interventional |
Phase 1 |
- National Eye Institute (NEI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
13 |
All |
Child, Adult, Senior |
NCT00001614 |
970146
97-EI-0146 |
|
July 1997 |
|
May 2000 |
December 10, 2002 |
March 4, 2008 |
|
- National Eye Institute (NEI)
Bethesda, Maryland, United States
|
| 31 |
NCT00836394 |
Completed |
Effect of Whole Body Vibration Therapy in Children With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Device: Galileo (whole body vibration (WBV) therapy)
|
Interventional |
Not Applicable |
- Children's Hospital of Eastern Ontario
- Canadian Arthritis Network
- University of Ottawa
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary objective is to evaluate the effect of whole body vibration therapy on muscle function by measuring the increase in z-score muscle power during a two leg jump as determined by jumping mechanography after 12 weeks compared to baseline.
- The increase in muscle force measured during a one leg jump as determined by jumping mechanography
- The increase in joint moment and power of the lower-limb measured in a gait lab using motion analysis
- (and 3 more...)
|
70 |
All |
7 Years to 18 Years (Child, Adult) |
NCT00836394 |
WBV-JIA |
WBV-JIA |
February 2009 |
January 2011 |
January 2011 |
February 4, 2009 |
June 28, 2011 |
|
- Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
|
| 32 |
NCT02991469 |
Suspended |
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (sJIA) |
- Juvenile Idiopathic Arthritis
|
- Drug: Sarilumab SAR153191 (REGN88)
|
Interventional |
Phase 2 |
- Sanofi
- Regeneron Pharmaceuticals
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of PK parameter: maximum serum concentration observed (Cmax)
- Assessment of PK parameter: Area under the serum concentration versus time curve calculated using the trapezoidal method during a dose interval (AUC0-t)
- Assessment of PK parameter: Concentration observed before treatment administration during repeated dosing (Ctrough)
- (and 13 more...)
|
36 |
All |
1 Year to 17 Years (Child) |
NCT02991469 |
DRI13926
2015-004000-35
U1111-1177-3584 |
|
March 30, 2018 |
August 2023 |
August 2023 |
December 13, 2016 |
December 12, 2017 |
|
- Investigational Site Number 8400410
Akron, Ohio, United States - Investigational Site Number 0320060
Buenos Aires, Argentina - Investigational Site Number 0320004
San Miguel De Tucuman, Argentina - (and 31 more...)
|
| 33 |
NCT02024334 |
Unknown † |
Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 4 |
- Mashhad University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- thirty percent changes in the ACR Pediatric core set of disease activity measures in at least three of the six response variables (ACR Pedi 30)
- 50% and 70% changes in the ACR Pediatric core set of disease activity measures in at least three of the six response variables (ACR Pedi 30)
|
30 |
All |
2 Years to 19 Years (Child, Adult) |
NCT02024334 |
900527 |
JIA |
June 2013 |
June 2014 |
December 2014 |
December 31, 2013 |
December 31, 2013 |
|
- Mashhad, Khorasan Razavi, Iran, Islamic Republic of
|
| 34 |
NCT02343770 |
Unknown † |
Biomarkers in Idiopathic Juvenile Arthritis |
- Idiopathic Juvenile Arthritis
|
- Other: blood sample for identifying biomarkers
|
Interventional |
Not Applicable |
- University Hospital, Montpellier
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- identification of specific autoantigen biomarkers
|
20 |
All |
2 Years to 16 Years (Child) |
NCT02343770 |
9355 |
|
June 2015 |
December 2015 |
December 2016 |
January 22, 2015 |
September 7, 2015 |
|
- Cardiology paediatric consultation, Arnaud de Villeneuve Hospital
Montpellier, France
|
| 35 |
NCT00090571 |
Unknown † |
Juvenile Rheumatoid Arthritis Research Registry |
- Juvenile Rheumatoid Arthritis
|
|
Observational |
|
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
NIH |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
|
200 |
All |
Child, Adult, Senior |
NCT00090571 |
NIAMS-102
N01-AR-42218
NIAMS-102;N01-04-03 |
|
October 1994 |
September 2009 |
|
August 30, 2004 |
June 9, 2009 |
|
- Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
| 36 |
NCT02776735 |
Recruiting |
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) |
- Juvenile Idiopathic Arthritis
|
- Drug: Sarilumab SAR153191 (REGN88)
|
Interventional |
Phase 2 |
- Sanofi
- Regeneron Pharmaceuticals
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of PK parameter: maximum serum concentration observed (Cmax)
- Assessment of PK parameter: Area under the serum concentration versus time curve calculated using the trapezoidal method during a dose interval (AUC0-t)
- Assessment of PK parameter: Concentration observed before treatment administration during repeated dosing (Ctrough)
- (and 5 more...)
|
36 |
All |
2 Years to 17 Years (Child) |
NCT02776735 |
DRI13925
2015-003999-79
U1111-1177-3487 |
|
September 6, 2016 |
April 2018 |
April 25, 2022 |
May 18, 2016 |
April 12, 2018 |
|
- Investigational Site Number 8400413
Durham, North Carolina, United States - Investigational Site Number 8400410
Akron, Ohio, United States - Investigational Site Number 8400412
Cleveland, Ohio, United States - (and 38 more...)
|
| 37 |
NCT02196480 |
Completed |
23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Seroprotection rate
- Seroconversion rate
- Number of participants with local and systemic adverse events
- Juvenile Arthritis Disease Activity Score with 27-joint reduced count (JADAS-27)
|
27 |
All |
5 Years to 18 Years (Child, Adult) |
NCT02196480 |
PPV23JIA-aTNF |
|
January 2008 |
June 2011 |
June 2012 |
July 22, 2014 |
July 22, 2014 |
|
- Centro de Dispensação de Medicamentos de Alto Custo (CEDMAC)
Sao Paulo, Brazil
|
| 38 |
NCT01986400 |
Completed |
Virtual Peer-to-Peer (VP2P) Support Mentoring for Juvenile Idiopathic Arthritis (JIA): A Pilot RCT |
- Juvenile Idiopathic Arthritis
|
- Behavioral: Virtual Peer-to-Peer Support Mentoring
|
Interventional |
Not Applicable |
- The Hospital for Sick Children
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Feasibility
- Health-Related Quality of Life (HRQL)
- Pain
- (and 3 more...)
|
30 |
All |
12 Years to 18 Years (Child, Adult) |
NCT01986400 |
1000038163 |
|
July 2013 |
May 2015 |
December 2016 |
November 18, 2013 |
January 3, 2018 |
|
- Hospital for Sick Children
Toronto, Ontario, Canada
|
| 39 |
NCT01434082 |
Unknown † |
Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Behavioral: comparison of types of sleep disordered breathing
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Prevalence of Sleep Disordered Breathing
- Measures of Daytime Sleepiness
|
150 |
All |
6 Years to 11 Years (Child) |
NCT01434082 |
JIA
1R01NR012734-01 |
JIA |
September 2011 |
January 2015 |
February 2015 |
September 14, 2011 |
September 14, 2011 |
|
- University of Washington School of Nursing
Seattle, Washington, United States
|
| 40 |
NCT02052167 |
Completed |
Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Device: methotrexate prefilled pen
|
Interventional |
Early Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- Evaluation of test case scenarios with observation and performance measures
|
30 |
All |
2 Years to 20 Years (Child, Adult) |
NCT02052167 |
MC-MTX.16/HF Children |
|
April 2014 |
August 2014 |
August 2014 |
January 31, 2014 |
March 29, 2018 |
|
- Children's Mercy Hospital & Clinics
Kansas City, Missouri, United States
|
| 41 |
NCT01015547 |
Completed |
Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Drug: Infliximab plus methotrexate
- Drug: Combination of DMARDs
- Drug: Methotrexate alone
|
Interventional |
Phase 3 |
- Helsinki University Central Hospital
- Foundation for Paediatric Research, Finland
- Päivikki and Sakari Sohlberg Foundation, Finland
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- ACR Pedi 75 response
- clinically inactive disease
- time spent in inactive disease
- (and 5 more...)
|
60 |
All |
4 Years to 15 Years (Child) |
NCT01015547 |
211864, 318/E0/2002
211864 |
ACUTE-JIA |
May 2003 |
November 2007 |
December 2013 |
November 18, 2009 |
October 15, 2015 |
|
- Rheumatism Foundation Hospital
Heinola, Finland - Hospital for Children and Adolescents
Helsinki, Finland - Kuopio University Hospital
Kuopio, Finland - (and 3 more...)
|
| 42 |
NCT01500551 |
Recruiting |
Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Standard laboratory safety data and adverse event (AE) reports. Body weight, height and Tanner Stages will collected to assess growth and physical development.
- Physician global evaluation of disease activity at each visit.
- Number of joints with active arthritis at each visit.
- (and 15 more...)
|
340 |
All |
2 Years to 18 Years (Child, Adult) |
NCT01500551 |
A3921145
2011-004915-22
JIA |
|
March 18, 2013 |
March 31, 2021 |
March 31, 2021 |
December 28, 2011 |
April 10, 2018 |
|
- Arkansas Children's Hospital- Attention: Jill Hernandez
Little Rock, Arkansas, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - Loma Linda University Children'S Hospital
Loma Linda, California, United States - (and 99 more...)
|
| 43 |
NCT01541917 |
Completed
Has Results |
Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Behavioral: Web-based coping skills training
- Behavioral: Online disease education
|
Interventional |
Phase 3 |
- Children's Mercy Hospital Kansas City
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Pain Intensity
- Change in PedsQL Rheumatology Health-Related Quality of Life Total Score
- Change in Medical Issues, Exercise, Pain and Social Support Questionnaire (MEPS) Education Score
- (and 3 more...)
|
305 |
All |
12 Years to 18 Years (Child, Adult) |
NCT01541917 |
GRANT10829275
1R01AR061513-01 |
WebSMART |
July 2012 |
April 2016 |
June 2016 |
March 1, 2012 |
March 9, 2017 |
March 9, 2017 |
- University of California San Francisco Benioff Children's Hospital
San Francisco, California, United States - Lurie Children's Hospital
Chicago, Illinois, United States - Riley Hospital for Children
Indianopolis, Indiana, United States - (and 7 more...)
|
| 44 |
NCT02165345 |
Active, not recruiting |
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Juvenile Arthritis Disease Activity Score (JADAS-71)
- Percentage of Participants With Adverse Events (AEs), Serious AEs (AEs) and AEs of Special Interest
- Childhood Health Assessment Questionnaire (CHAQ) Score
- Percentage of Participants With Protocol Defined Inactive Disease/Clinical Remission
|
96 |
All |
2 Years to 18 Years (Child, Adult) |
NCT02165345 |
WA29231
2013-005212-98 |
|
July 16, 2014 |
November 6, 2020 |
November 6, 2020 |
June 17, 2014 |
January 12, 2018 |
|
- Arkansas Children's Hospital Research Institute
Little Rock, Arkansas, United States - University of Chicago Hospital
Chicago, Illinois, United States - Hackensack University Medical Center; Pediatric Rheumatology
Hackensack, New Jersey, United States - (and 28 more...)
|
| 45 |
NCT01357668 |
Recruiting |
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence rate of serious infections
- Incidence rate of malignancies
- Incidence rate of autoimmune disorders
- (and 2 more...)
|
900 |
All |
up to 17 Years (Child) |
NCT01357668 |
IM101-240 |
|
January 31, 2013 |
December 31, 2029 |
December 31, 2029 |
May 23, 2011 |
April 4, 2018 |
|
- Arkansas Children's Hospital
Little Rock, Arkansas, United States - Children's Hospital Los Angeles
Los Angeles, California, United States - Florida University
Gainesville, Florida, United States - (and 79 more...)
|
| 46 |
NCT01904292 |
Completed |
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Tocilizumab
- Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Tocilizumab
- Pharmacokinetics: Minimum Plasma Concentration (Cmin) of Tocilizumab
- (and 6 more...)
|
52 |
All |
1 Year to 17 Years (Child) |
NCT01904292 |
WA28118
2012-003490-26 |
|
August 15, 2013 |
June 13, 2017 |
June 13, 2017 |
July 22, 2013 |
November 20, 2017 |
|
- Arkansas Children's Hospital Research Institute
Little Rock, Arkansas, United States - Connecticut Children's Medical Center; 5E Clinical Trials Unit
Hartford, Connecticut, United States - Ann & Robert H. Lurie Children's Hospital of Chicago; Division of Rheumatology
Chicago, Illinois, United States - (and 39 more...)
|
| 47 |
NCT01287715 |
Unknown † |
Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 4 |
- Erasmus Medical Center
- Dutch Arthritis Association
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Flare-rate
- Duration of remission before withdrawal of etanercept
- Predictors for successful discontinuation of etanercept
- Disease course after flaring
|
50 |
All |
4 Years to 17 Years (Child) |
NCT01287715 |
NR 10-1-203 |
ABC-STOP |
January 2011 |
September 2012 |
September 2013 |
February 1, 2011 |
February 1, 2011 |
|
- Academic Medical Centre Emma Children's Hospital
Amsterdam, Netherlands - Reade Institute Amsterdam
Amsterdam, Netherlands - Sint-Lucas Andreas Hospital
Amsterdam, Netherlands - (and 7 more...)
|
| 48 |
NCT01904279 |
Completed
Has Results |
A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA) |
- Juvenile Idiopathic Arthritis
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Minimum Serum Concentration (Cmin) of TCZ at Steady State
- Area Under the Curve at Steady-state Over a 12-week Interval (AUC12weeks) of TCZ Treatment
- Maximum Serum Concentration (Cmax) of TCZ at Steady State
- (and 5 more...)
|
52 |
All |
1 Year to 17 Years (Child) |
NCT01904279 |
WA28117
2012-003486-18 |
JIGSAW 117 |
July 2013 |
May 2016 |
May 2016 |
July 22, 2013 |
June 14, 2017 |
March 16, 2017 |
- Hartford, Connecticut, United States
- Chicago, Illinois, United States
- Chicago, Illinois, United States
- (and 32 more...)
|
| 49 |
NCT01563185 |
Completed
Has Results |
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis |
- Juvenile Idiopathic Arthritis
|
- Drug: 800 mg ibuprofen/26.6 mg famotidine
|
Interventional |
Phase 4 |
- Horizon Pharma Ireland, Ltd., Dublin Ireland
- Pediatric Rheumatology Collaborative Study Group
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs)
- Childhood Health Questionnaire Parent Form 50 (CHQ-PF50) Scores
- American College of Rheumatology (ACR) Pediatric Core Measures: Physician's Global Assessment of Disease Activity and Parent's Assessment of Overall Well-being
- (and 8 more...)
|
12 |
All |
10 Years to 16 Years (Child) |
NCT01563185 |
HZ-CA-402 |
|
April 2012 |
March 2015 |
March 2015 |
March 26, 2012 |
December 23, 2015 |
December 23, 2015 |
- Children's Hospital
New Orleans, Louisiana, United States - Floating Hospital for Children @ Tufts Medical Center
Boston, Massachusetts, United States - UMASS Memorial Children's Medical Center
Worcester, Massachusetts, United States - (and 2 more...)
|
| 50 |
NCT01676948 |
Withdrawn |
An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) |
- Systemic Juvenile Idiopathic Arthritis
|
- Drug: ACZ885
- Drug: Canakinumab
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- PRINTO / PRCSG
- Novartis
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Long-term safety and tolerability of canakinumab and the retention rate of canakinumab-treated patients
- The percentage of patients who meet the adapted pediatric ACR, its individual components, and the Juvenile Arthritis Disease Activity Score [JADAS] over time
- The level of systemic corticosteroid tapering achieved in Part I
- (and 2 more...)
|
0 |
All |
2 Years to 20 Years (Child, Adult) |
NCT01676948 |
CACZ885G2402
2012-003054-92 |
β-SPECIFIC 4Pa |
January 2013 |
January 2015 |
January 2015 |
August 31, 2012 |
October 15, 2015 |
|
|
Create an RSS feed from your search for:
Download the search results for: